Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Capital Expenditures: 2013-2024

Historic Capital Expenditures for Akebia Therapeutics (AKBA) over the last 11 years, with Dec 2024 value amounting to $33,000.

  • Akebia Therapeutics' Capital Expenditures rose 3750.00% to $77,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $223,000, marking a year-over-year increase of 9.31%. This contributed to the annual value of $33,000 for FY2024, which is N/A change from last year.
  • Per Akebia Therapeutics' latest filing, its Capital Expenditures stood at $33,000 for FY2024, which was down 71.05% from $114,000 recorded in FY2022.
  • Akebia Therapeutics' 5-year Capital Expenditures high stood at $317,000 for FY2020, and its period low was $33,000 during FY2024.
  • Over the past 2 years, Akebia Therapeutics' median Capital Expenditures value was $73,500 (recorded in 2022), while the average stood at $73,500.
  • In the last 5 years, Akebia Therapeutics' Capital Expenditures crashed by 95.24% in 2020 and then soared by 93.22% in 2022.
  • Akebia Therapeutics' Capital Expenditures (MRY) stood at $317,000 in 2020, then tumbled by 81.39% to $59,000 in 2021, then surged by 93.22% to $114,000 in 2022, then tumbled by 71.05% to $33,000 in 2024.
  • Its Capital Expenditures stands at $33,000 for FY2024, versus $114,000 for FY2022 and $59,000 for FY2021.